What one share of Janux Therapeutics holds
We are an innovative clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying our proprietary technologies to our Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms.
Janux Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.38 |
|---|---|
| Profit | −$1.64 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.67 |
| Cash and investments | $0.45 |
| Book value | $15.19 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | $0.15 | −$1.39 | $0.06 | −$0.78 | — | $8.88 |
| 2022 | $0.21 | −$1.52 | $0.16 | −$1.19 | — | $7.71 |
| 2023 | $0.18 | −$1.32 | $0.04 | −$1.19 | — | $7.45 |
| 2024 | $0.20 | −$1.28 | $0.01 | −$0.82 | — | $17.32 |
| 2025 | $0.16 | −$1.83 | $0.02 | −$1.34 | — | $15.85 |
Common questions about Janux Therapeutics
How much does one share of Janux Therapeutics earn?
Over the last 12 months, Janux Therapeutics lost $1.64 for each share on $0.38 of sales.
Does Janux Therapeutics pay a dividend?
Janux Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Janux Therapeutics’s book value per share?
Janux Therapeutics’s book value is $15.19 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Janux Therapeutics have?
Each share of Janux Therapeutics has $0.45 of cash and investments, as of June 30, 2026.
What is Janux Therapeutics’s free cash flow per share?
−$0.67 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Janux Therapeutics bought back shares?
Janux Therapeutics’s share count rose about 163% from 2021 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.